Items where authors include "Corrie, P."

Article

Mukherjee, S., Qi, C., Shaw, R. et al. (20 more authors) (2024) Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial. European Journal of Cancer, 209. 114236. ISSN 0959-8049

Sacco, J.J., Jackson, R., Corrie, P. et al. (18 more authors) (2024) A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma. European Journal of Cancer, 202. 114009. ISSN 0959-8049

Dayimu, A. orcid.org/0000-0001-9998-7463, Gupta, A., Matin, R.N. et al. (25 more authors) (2024) A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM). European Journal of Cancer, 196. 113455. ISSN 0959-8049

Lee, R.W., Danson, S. orcid.org/0000-0002-3593-2890, Elliot, M. et al. (8 more authors) (2022) Importance of clinical research for the UK's 10-year cancer plan. The Lancet Oncology, 23 (8). pp. 975-978. ISSN 1470-2045

Coen, O., Corrie, P., Marshall, H. et al. (17 more authors) (2021) The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma. BMC Cancer, 21 (1). 761. ISSN 1471-2407

Danson, S. orcid.org/0000-0002-3593-2890, Hook, J., Marshall, H. et al. (4 more authors) (2019) Are we over-treating with checkpoint inhibitors? British Journal of Cancer, 121 (8). pp. 629-630. ISSN 0007-0920

Urbonas, V., Schadendorf, D., Zimmer, L. et al. (11 more authors) (2019) Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial. Annals of Oncology, 30 (2). pp. 317-324. ISSN 0923-7534

Corrie, P., Marshall, A., Dunn, J. et al. (17 more authors) (2014) Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. Lancet Oncology, 15 (6). pp. 620-630. ISSN 1470-2045